US EditionPublished • loading... • Updated
Current and Future Medications for Obesity Treatment
Summary by JAMA Network
3 Articles
3 Articles
Diabetes, one of the greatest threats to public health, was the central theme of the discussion organized by Antena 3 CNN, an event that brought together ministers, experts, representatives of your...
JCI GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
Glucagon-like peptide-1 (GLP-1) was initially considered to be a hormone with a predominant role in regulating glucose metabolism by inducing insulin secretion, reducing glucagon secretion, and ameliorating insulin resistance, with the last effect being largely dependent on the induction of weight loss. In more recent years, the role of this peptide beyond metabolism has progressively been explored, including its impact on kidney physiology and …
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
